I think Takeda used MUFG when they swallowed Shire, although compared to the $62Bn Shire acquisition, Prana would be barely a blip on the radar. The market PBT434 is going after is big even by pharma standards. Morgan Stanley was advising Shire. Just saying. Is it possible the price was hammered down for a reason?